Federal Court rejects ToolGen’s genome editing patent

Intellectual Property 2023-07-20 9:49 pm | Sydney
A judge has upheld findings from IP Australia that South Korean biotech ToolGen’s genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.
For information on rights and reprints, contact subscriptions@lawyerly.com.au